MDACC Study No:2010-0964 ( NCT No: NCT01317875)
Title:A Phase Ib, open-label, dose-finding study of the JAK
inhibitor ruxolitinib tablets administered orally to patients with
Primary Myelofibrosis (PMF), Post-Polycythemia Vera-
Myelofibrosis (PPV-MF) or Post-Essential
Thrombocythemia-Myelofibrosis (PET-MF) and baseline
platelet counts >/= 50x10^9/L and <100x10^9/L.
Principal Investigator:Srdan Verstovsek
Treatment Agent:Ruxolitinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable
starting dose of ruxolitinib that can be given to patients with myelofibrosis
who have thrombocytopenia. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase I
Treatment Agents:Ruxolitinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Incyte Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults